Focus of research
[Forschungslinie 1]: Bioanalytics & Microdialysis and Cellculture
The central topic of my research project is the optimisation of the anti-infective therapy. In scientific research, drug concentrations of most of the anti-infectives are determined from serum and blood samples directly taken from the bloodstream. The microdialysis technique is an alternative to determine the drug concentrations directly at the target-site e.g. in muscle and subcutaneous adipose tissue. The benefit of this method is to gain knowledge about the pharmacokinetics at the target-site while plasma concentrations serve only as surrogate parameters. Since only unbound drug molecules are able to pass the semipermeable membrane of the microdialysis catheter only the pharmacological active fraction of the drug is collected. Thus, only the active drug fraction can be quantified at the target-site.
Anidulafungin is an echinocandin antifungal drug and is used for the treatment of invasive candidiasis in non-neutropenic adult patients. In a first step, anidulafungin will be characterised in vitro by microdialysis to establish the basis for the following in vivo studies investigated by our collaboration partner at the Medical University Vienna.
In the course of in vitro characterisation different study conditions will be investigated, e.g. perfusate composition, flow rate of perfusate and type of probe. The aim is to perform several in vivo studies in different body fluids such as interstitial fluid of subcutaneous adipose tissue, muscle tissue, in saliva, ascitic fluid and epithelial lining fluid.
In order to analyse anidulafungin reliably from in vitro as well as from in vivo microdialysis samples a bioanalytical HPLC assay will be established and validated in accordance to the “EMA: Guideline for bioanalytical method validation“.